# The Readout Loud (@thereadoutloud)

Podcast on Boilpoints

Page: https://boilpoints.com/u/thereadoutloud

## Latest segments

- [RasenQ's price tag](https://boilpoints.com/point/rasenqs_price_tag_2868334425), 2026-10-30: **Surveys the wider KRAS field the approval opened**. Surveys the wider KRAS field the RasenQ approval opened up: G12D inhibitors such as Insilico's combined with chemotherapy in pancreatic cancer, and a debate over mutation-specific versus pan-KRAS drugs. Frames the approval as the starting gun rather than the finish line.
- [Moderna cancer vaccine leak](https://boilpoints.com/point/moderna_cancer_vaccine_leak_2631450642), 2026-10-30: **Recaps the embargo break and the sell-off**. Recaps the embargo break and the sell-off, framing the drop as a market reaction after Moderna added about $60 billion in market value since August, not a verdict on the data. Stays inside the leak coverage already on the record.
- [Moderna-Merck vaccine data](https://boilpoints.com/point/moderna_merck_vaccine_data_3187597673), 2026-10-30: **Adds the cost and access questions**. Turns to cost and access: Keytruda's decade as standard of care, copycat versions due in a few years, and the vaccine's expected hefty price tag. Drew's sit-down with Bancel adds the pipeline map - kidney cancer data at year-end or early next year, lung cancer as the big test.
- [Moderna-Merck vaccine data](https://boilpoints.com/point/moderna_merck_vaccine_data_3187597673), 2026-10-30: **Walks through the 42% progression reduction**. Walks through the ESMO readout of the intismeran-Keytruda data: the 42% reduction in disease progression versus Keytruda alone in adjuvant melanoma, and the debate over how broadly personalized cancer vaccines will work. A retelling of the disclosed numbers, with the vaccine's name and the conference setting added.
- [NIH peer review score proposal](https://boilpoints.com/point/nih_peer_review_score_proposal_331712654), 2026-10-08: **Interviews reporters on NIH's discretionary funding shift**. Interviews a STAT reporter and an AAMC policy lead on how the NIH actually spent its 2026 budget: the shift from peer review scores to program officer and institute director discretion, the December 2025 unified funding strategy, and the collapse in health disparities and race-related awards.